Martek/Abbott exclusive supply deal
This article was originally published in The Tan Sheet
Executive Summary
Martek Biosciences will serve as exclusive worldwide supplier of DHA and ARA for Abbott Nutrition's infant formula products, including Similac Advance, under a new, long-term supply agreement announced Oct. 8. Abbott signed a 25-year, non-exclusive supply agreement with Martek in 2000 that will remain in effect (1"The Tan Sheet" Sept. 29, 2003, p. 14). The new deal provides for a 10-year term, though Abbott can terminate as of January 2012. Martek's life'sDHA and life'sARA ingredients are used in more than 95% of U.S. infant formulas...
You may also be interested in...
Martek Pursues Cheaper DHA Cost Structure To Give Ingredient Wider Appeal
Martek Biosciences is working toward substantially lowering the cost of making docosahexaenoic acid (DHA) through a business venture with a genetics seed company
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.